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Abstract
Objective: The aim of this study was to determine the association of the pancreatic steatosis with 
obesity, chronic pancreatitis (CP), and type 2 diabetes mellitus.
Methods: Patients (n = 118) were retrospectively identified and categorized into no CP (n = 60), 
mild (n = 21), moderate (n = 27), and severe CP (n = 10) groups based on clinical history and 
magnetic resonance cholangiopancreatography using the Cambridge classification as the 
diagnostic standard. Visceral and subcutaneous compartments were manually segmented, and fat 
tissue was quantitatively measured on axial magnetic resonance imaging.
Results: Pancreatic fat fraction showed a direct correlation with fat within the visceral 
compartment (r = 0.54). Patients with CP showed higher visceral fat (P = 0.01) and pancreatic fat 
fraction (P < 0.001): mild, 24%; moderate, 23%; severe CP, 21%; no CP group, 15%. Patients with 
type 2 diabetes mellitus showed higher pancreatic steatosis (P = 0.03) and higher visceral (P = 
0.007) and subcutaneous fat (P = 0.004). Interobserver variability of measuring fat by magnetic 
resonance imaging was excellent (r ≥ 0.90–0.99).
Conclusions: Increased visceral adipose tissue has a moderate direct correlation with pancreatic 
fat fraction. Chronic pancreatitis is associated with higher pancreatic fat fraction and visceral fat. 
Type 2 diabetes mellitus is associated with higher pancreatic fat fraction and visceral and 
subcutaneous adiposity.
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Pancreatic steatosis, which comprehends fatty replacement and fatty infiltration of the 
pancreas, is a commonly observed but often neglected finding by radiologists. The estimated 
prevalence of pancreatic steatosis from population-based studies in Asia is approximately 
16%.1,2 A higher prevalence has been noted in hospital-based populations and those with 
type 2 diabetes mellitus (T2DM) and obesity.3,4 There is notable evidence from both the 
pathological and imaging point of view that pancreatic steatosis is an increasing problem 
due to increasing incidence of obesity.3,5 Obesity is a heterogeneous condition that may 
manifest itself with considerable individual differences regarding distribution of body fat. 
Much of previous research has focused on the association between obesity with metabolic 
syndrome, cardiovascular risk, diabetes, and hepatic steatosis.6 The association of abdominal 
fat distribution with the development of pancreatic steatosis and chronic pancreatitis (CP) is 
underinvestigated and not clear. A recent study reported an association between pancreatic 
steatosis, visceral fat, and metabolic syndrome using computed tomography and ultrasound.7 
Using different fat quantification techniques of the magnetic resonance imaging (MRI), the 
pancreatic fat fraction can be reliably quantified8 with higher accuracy than computed 
tomography and ultrasound.9 To our knowledge, there have been no studies that investigated 
the correlation of pancreatic steatosis with the distribution of abdominal fat using precise fat 
quantification methods of MRI. The purpose of this study was to determine the association 
of the pancreatic steatosis with obesity, CP, and T2DM.
MATERIALS AND METHODS
Patient Selection
This study was approved by the institutional review board and complied with the Health 
Insurance Portability and Accountability Act. We retrospectively identified 143 consecutive 
patients who presented to a tertiary referral center for pancreatic diseases and had an 
magnetic resonance cholangiopancreatography (MRCP) examination within a month of their 
visit between May 2016 and February 2017 (Fig. 1). Patients who presented to the 
gastroenterology clinic (n = 113) had unexplained upper abdominal pain suspected to be of 
pancreatic in origin as described in the American Pancreatic Association guidelines.10 The 
remaining 30 patients were enrolled in the pancreatic cancer screening program. These 
patients were annually screened with MRI/MRCP for pancreatic cancer due to either family 
history of pancreatic cancer or having a genetic predisposition (eg, presence of germline 
BRCA mutation) for pancreatic cancer. These patients were otherwise healthy and screened 
with amylase, lipase, aspartate aminotransferase, alkaline phosphatase, carcinoembryonic 
antigen, carbohydrate antigen 19–9, and C-peptide before enrolling in the program. Of the 
143 patients, 118 were included in the analysis after 25 patients were excluded secondary to 
the diagnosis of pancreatic cancer (n = 1), acute pancreatitis (n = 17), artifacts affecting the 
pancreas (n = 4), and previous pancreatic surgery (n = 3). Data on T2DM status, body mass 
index (BMI), weight, hyperlipidemia, smoking, and alcohol use were obtained from the 
electronic medical records.
This study categorized the patients based on MRCP ductal findings using the Cambridge 
classification as the diagnostic standard.11 Cambridge 0 patients comprised the no-disease 
group (n = 60), whereas the patients in the Cambridge 2 (mild CP), 3 (moderate CP), and 4 
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(severe CP) were combined as the disease group (n = 58). There were no patients with 
Cambridge grade 1 (ie, equivocal or 1–2 side-branch ectasias).
Imaging Technique
All patients were imaged on the 3-T MRI scanner (Magnetom Verio; Siemens Healthcare 
GmbH, Erlangen, Germany) using the same imaging protocol. Imaging parameters of the 
axial breath-hold 2-point DIXON T1-weighted images were as follows repetition time, 5.45 
milliseconds; echo time 1, 2.45 milliseconds; echo time 2, 3.675 milliseconds; flip angle, 9°; 
and slice thickness, 4 mm. Secretin (ChiRhoStim; ChiRhoClin Inc, Burtonsville, Md) was 
given in all patients to enhance the visualization of the pancreatic ducts using the 
manufacturer-recommended dose of 16 μg. Pancreatic ducts were imaged via coronal 2-
dimensional single-shot turbo spin echo sequence, which was repeated every 60 seconds up 
to 10 minutes. Patients were fasting at least 4 hours before the MRCP. No adverse events 
were identified.
Image Data Analysis
Two image analysts collected data, and 1 abdominal radiologist with 16 years of experience 
graded the MRCP findings using Cambridge classification. All DICOM Dixon images were 
deidentified and imported into Analyze 12.0 (AnalyzeDirect, Stilwell, Kan) for image 
processing. See the supplemental materials http://links.lww.com/MPA/A706, for step-by-
step details of the image postprocessing. Image analysts who performed region-of-interest 
measurements were blinded to the patient information. The pancreatic fat fraction was 
calculated by measuring signal intensity on the fat-only and water-only fractions of the T1-
weighted axial breath-hold 2-point Dixon series.12 Visceral adipose tissue (VAT) is defined 
as intra-abdominal fat (including intraperitoneal and retroperitoneal fat) bound by parietal 
peritoneum or transversalis fascia, excluding the vertebral column and the paraspinal 
muscles. The subcutaneous adipose tissue (SAT) is defined as fat superficial to the 
abdominal and back muscles. The pancreatic and abdominal segmentation was verified by 
the abdominal radiologist.
Statistical Analysis
Fisher-Freeman-Halton, Kruskal-Wallis, and Mann-Whitney-Wilcoxon tests were used to 
determine differences between the 4 groups. Spearman rank correlation coefficient was used 
to assess relationships between the independent variables and interob-server concordance. 
Correlation coefficients were interpreted as follows: weak, 0.2; moderate, 0.5; strong, 0.8; 
and perfect, 1.0.13 Receiver operating characteristic curves and multivariate logistic model 
were used to compare different models. Conventional risk factors for diabetes and CP (age, 
alcohol, smoking, hyperlipidemia, and BMI) were included in the base model of multivariate 
logistic regression. Likelihood ratio tests were used in assessing each new measure to be 
added to the logistic models. Youden index was used for determining threshold values of 
pancreatic fat. Probit regression was used to estimate the probability of CP and T2DM. The 
predicted probability was plotted for each model to demonstrate the effectiveness of each 
measure alone. Statistical analyses were performed using MedCalc version 18.2.1 (MedCalc 
Software, Mariakerke, Belgium) and R software version 3.3.0 (R Foundation, Vienna, 
Austria).
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RESULTS
The patients’ age, sex, amylase, lipase, BMI, weight, and other independent variables are 
listed in Table 1, and comparisons of results in the disease versus no-disease groups are 
presented in Table 2. Distribution of patient’s sex was similar in patients with and without 
CP (P = 0.30) and T2DM (P = 1.0). Patients in the CP group were older (age, 60 years; 
range, 22–75 years; P < 0.001) than those in the no CP group (age, 50 years; range, 19–78 
years). Patients with and without T2DM had similar age (57 vs 55 years, respectively, P = 
0.58). Interobserver variability for measuring pancreatic fat determined by the Spearman 
rank correlation was excellent (r = 0.90).
Pancreatic Fat and Visceral Adiposity
Pancreatic fat fraction showed a moderate positive correlation (r = 0.54) with VAT (Fig. 2). 
There was a weak correlation of pancreatic fat with the SAT (r = 0.23) and visceral-to-
subcutaneous adiposity ratio (V/S) (r = 0.26) (Fig. 3).
Pancreatic Fat and CP
Patients in the no CP group showed significantly lower pancreatic fat fraction (15%; 95% 
confidence interval [CI], 14%–17%) compared with the groups with mild CP (24%; 95% CI, 
21%–27%; P < 0.0001), moderate CP (23%; 95% CI, 20%–25%; P < 0.0001), and severe CP 
(21%; 95% CI, 16%–26%; P = 0.02). Pancreatic fat fraction between the mild, moderate, 
and severe CP groups was statistically similar (P = 0.48) (Fig. 4). Multivariate logistic 
analysis (Fig. 5A) showed that pancreatic fat has the highest diagnostic potential for CP 
(area under the curve [AUC], 0.83), followed by VAT (AUC, 0.72) and SAT (AUC, 0.70). 
Pancreatic fat fraction of 56% was 74% sensitive and 85% specific for CP.
Pancreatic Fat and T2DM
Patients with T2DM showed higher pancreatic fat (23%; 95% CI, 21%–25%) as compared 
with the no-diabetes group (15%; 95% CI, 14%–17%; P = 0.03). Multivariate logistic model 
analysis including pancreatic fat, SAT, VAT, and V/S showed that pancreatic fat has the 
highest diagnostic potential for T2DM (AUC, 0.85), closely followed by VAT (AUC, 0.84), 
SAT (AUC, 0.82), and V/S (AUC, 79) (Fig. 5B). Fat fraction of 24% was 69% sensitive and 
87% specific for T2DM.
Visceral Adiposity, CP, and T2DM
Chronic pancreatitis patients had higher VAT (172 cm2; 95% CI, 150–194 cm2) compared 
with the no CP group (138 cm2; 95% CI, 118–158 cm2; P = 0.01) (Table 2). A higher VAT 
was also seen in patients with T2DM (202 cm2; 95% CI, 158–247 cm2) compared with those 
without T2DM (146 cm2; 95% CI, 131–161 cm2). A higher SAT was seen in T2DM (P = 
0.004) but not in the CP group (P = 0.13) (Table 2). The V/S ratio was not a significant 
factor for either CP (P = 0.35) or T2DM (P = 0.80).
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Other Factors
There was a weak positive correlation between the pancreatic fat fraction and age in the no-
disease group (r = 0.33, P = 0.01). The weak correlations between the age and VAT (r = 
0.21, P = 0.10), SAT (r = 0.05, P = 0.69), and V/S (r = 0.16, P = 0.22) were not statistically 
significant. There was a weak correlation of the pancreatic fat with BMI (r = 0.12), but this 
was not statistically significant (P = 0.20). Patients with history of smoking showed higher 
pancreatic fat (P ≤ 0.01), and smoking had a strong association with CP (P = 0.005). Alcohol 
consumption was higher in patients with CP (P = 0.03) and T2DM (P = 0.03), whereas 
hyperlipidemia was associated with T2DM only (P = 0.006).
Probability Analysis
Figure 6 shows predicted probability curves for pancreatic steatosis, CP, and T2DM as a 
dose-response analysis. The probability of CP increases together with the amount of VAT 
(Fig. 6A) and with pancreatic fat fraction (Fig. 6B). Increasing pancreatic fat fraction also 
increases the probability of T2DM (Fig. 6C).
DISCUSSION
Extensive research has been done on hepatic steatosis showing its association with 
abdominal obesity. Interest in pancreatic steatosis and its clinical significance has gained 
attention only in recent years. Some studies emphasized the importance of pancreatic 
steatosis by reporting that exposure of pancreatic islets to increased fatty acids causes β-cell 
dedifferentiation, and this is likely the underlying mechanism for T2DM.14–16 Magnetic 
resonance imaging has superior in vivo sensitivity for quantification of fat compared with 
computed tomography and ultrasound.17–19 In this study, we quantitatively measured 
pancreatic steatosis and abdominal fat by MRI and analyzed the relationship among the 
pancreatic steatosis, abdominal fat, CP, and T2DM.
Pancreatic Fat Content and CP
Our results showed that patients with CP were more likely to have higher pancreatic fat, but 
this relationship was not linear with the severity of CP. In vitro and animal model studies 
suggest that pancreatic lipomatosis may contribute to β-cell lipotoxicity and lipoapoptosis, 
with consequent loss of function.20 However, data on humans are inconsistent. Unlike the 
liver, where the triglycerides accumulation is mainly intracellular, pancreatic steatosis is 
histologically characterized by an increased number of adipocytes.21 However, the 
intracellular fat accumulation can be visualized by electronic microscopy or 
immunohistochemistry in both acinar and islet cells and may precede adipocytes infiltration.
20,22
 It is unknown if intracellular or extracellular triglycerides have a different clinical 
significance, but it is possible that adipocytes influence the function of acinar and islet cells 
by a paracrine effect, whereas intracellular lipids may lead to lipotoxicity and therefore islet 
or acinar cells injury.23,24 Based on the review of the literature and findings of our cross-
sectional study, the possibility of steatopancreatitis as an etiological factor for CP and T2DM 
can be considered. However, proof of this association will require histopathologic 
confirmation, which is usually performed in human studies.
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Pancreatic Fat Content and T2DM
There has been a dearth of studies on the relationship between pancreatic fat and exocrine 
pancreatic disease, although experts alluded this to a hypothetical relationship.25 In a study 
of patients with T2DM, pancreatic fat content was not linearly correlated with exocrine 
pancreatic function, as measured by pancreatic enzymes, or bicarbonate secretion.26 The 
null finding may have been due to the assumption of a linear relationship, when in fact the 
relationship may be nonlinear, as evident in our study.
Whereas some of the prior studies have investigated the clinical impact of pancreatic fat and 
how it is related to endocrine pancreatic function,2,27,28 our study looked into this 
relationship in the context of visceral adiposity and pancreatic steatosis, which 
independently could influence the risk of T2DM. We found that T2DM had the highest 
association with pancreatic steatosis, closely followed by VAT, SAT, and V/S. These findings 
are consistent with studies that have examined pancreatic fat and T2DM,4,29 most of which 
point to a positive association between the 2 conditions with a summary odds ratio of 2. Our 
results contradict with a large cohort study that did not find a relationship between the 
T2DM and pancreatic steatosis.18 However, that study was population based, and recruited 
volunteers and the number of T2DM patients were very small.
Studies on the relationship between pancreatic fat and endocrine dysfunction have been 
inconsistent. In the largest study to date, Ou et al29 investigated 7464 subjects using 
ultrasound and found that subjects with T2DM were more likely to have pancreatic fat, 
which agrees with our results. Postmortem studies18,30 found no association between 
pancreatic fat and T2DM. Pancreatic fat measured in postmortem settings may not 
accurately portray the level of fat because pancreatic tissue degrades rapidly after death. 
Heni et al27 demonstrated that pancreatic fat is negatively associated with insulin secretion, 
whereas Wong et al2 showed that persons with fatty pancreas were more likely to have 
insulin resistance. van der Zijl et al28 found no direct relationship between pancreatic fat and 
β-cell function. North American Pancreatitis 2 study showed that CP, exocrine insufficiency, 
calcifications, and pancreas surgery conveyed higher odds of having diabetes.31 However, 
the traditional risk factors of obesity and family history were similarly important in the latter 
study.
Pancreatic Fat Content and Abdominal Fat Distribution
The association of the abdominal fat distribution with pancreatic fat is underinvestigated. 
Our study showed that abdominal obesity and pancreatic fat are related, with the highest 
correlation being with visceral obesity. This finding supports the hypothesis that pancreatic 
fat is exacerbated by visceral fat and has an impact on pancreatic disease, independent of 
general obesity. This is also consistent with the literature reporting that ectopic fat content of 
the pancreas is independent of BMI.32 In our study, BMI or total body weight was not a 
significant factor for CP or T2DM as there was a weak correlation of the pancreatic fat with 
BMI (r = 0.12). Previous studies acknowledge that the correlation between BMI and visceral 
obesity can vary considerably.33 It has been suggested that individual differences in visceral 
fat remain considerable, even when subjects with relatively similar BMI and percent body 
fat are investigated.34
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This study was limited by its retrospective design and limited patient population size. For 
measurement of pancreatic fat content, we used T1-weighted 2-point Dixon series. Although 
Dixon technique is very accurate, prospective studies can be performed using proton density 
fat fraction, which could be more precise. Most studies used the level of the L4/L5 lumbar 
vertebra for intra-abdominal fat measurements to capture the highest percentage of the body 
fat. This study measured the abdominal fat at the level of the pancreas. There were 2 reasons 
for this; MRI/MRCP usually does not extend to the level of the L4/L5 vertebra, and we were 
interested in finding the correlation between the abdominal and pancreatic fat, rather than 
measuring the highest amount of fat in the abdomen. Finally, our study was cross-sectional. 
Thus, we were not able to establish the temporal relationship between pancreatic steatosis, 
CP, and T2DM. Future longitudinal studies—including those emerging from the Chronic 
Pancreatitis, Diabetes, and Pancreatic Cancer research consortium—will be necessary to 
establish a causal relationship between pancreatic fat and CP.
In summary, this study demonstrated that increased VAT has a moderate direct correlation 
with pancreatic fat fraction. Chronic pancreatitis is associated with higher pancreatic fat 
fraction and visceral fat. Type 2 diabetes is associated with higher pancreatic fat fraction and 
visceral and subcutaneous adiposity.
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FIGURE 1. 
Patient selection algorithm. Categorization of the patient groups was done by secretin-
enhanced MRCP using the Cambridge classification as the diagnostic standard. Cambridge 0 
patients comprised the no CP group.
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FIGURE 2. 
Correlation of pancreatic fat fraction and visceral fat amount. This plot shows the moderate 
correlation between the pancreatic and visceral fat (r = 0.54, P < 0.0001), which is stronger 
than the SAT and V/S.
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FIGURE 3. 
Correlation of abdominal fat content within the visceral (VAT) and subcutaneous (SAT) 
compartments, V/S, and pancreatic fat fraction (PS). Low to moderate correlations were 
observed between each pair. The highest correlation was between the VAT and pancreatic 
fat. NA indicates not applicable.
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FIGURE 4. 
Box-and-whisker plot showing the distribution of pancreatic fat fraction in the no CP, mild, 
moderate, and severe CP groups. Patients with CP showed significantly higher percentage of 
pancreatic fat compared with the no CP group. Pancreatic fat fractions in the mild (average, 
24%), moderate (23%), and severe CP (21%) groups were significantly higher than normal 
group (15%), with the highest difference between the no CP and mild CP group. There was 
no statistically significant difference in the fat fraction between the CP groups (P = 0.48).
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FIGURE 5. 
Multivariate logistic regression analysis is showing the association between the pancreatic 
steatosis (PS) and distribution of the abdominal fat with CP (A) and T2DM (B). A, 
Multivariate logistic model analysis of CP with base model, PS, VAT, SAT, and V/S. Base 
model included these conventional risk factors: alcohol, smoking, and BMI. Pancreatic 
steatosis has the highest diagnostic potential for CP (AUC,0.83), followed by VAT (AUC, 
0.72) and SAT (AUC, 0.70). Using pancreatic fat fraction of 56% as the threshold, PS was 
74% sensitive and 85% specific for CP. B, Multivariate logistic regression analysis of T2DM 
with PS, VAT, SAT, and V/S. Base model included these conventional risk factors: alcohol, 
hyperlipidemia, and BMI. Pancreatic steatosis has the highest diagnostic potential for T2DM 
(AUC, 0.85), closely followed by VAT (0.84), SAT (AUC, 0.82), and V/S (AUC, 0.79). 
Using pancreatic fat fraction of 24% as the threshold, PS was 69% sensitive and 87% 
specific for T2DM.
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FIGURE 6. 
These 3 diagrams are created using probit regression to analyze the dose-response analysis 
between the visceral adiposity, pancreatic fat fraction, and T2DM. The probit regression 
procedure fits a probit sigmoid dose-response curve and calculates values (with 95% CI) of 
the dose variable that corresponds to a series of probabilities. A, Predicted probability curve 
of visceral adiposity (VAT measured as cm2) and CP. B, Predicted probability curve of 
pancreatic fat fraction and CP. C, Predicted probability curve of pancreatic fat fraction and 
T2DM.
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